Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

Avidity Partners

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 48
Average round size
info
The average size of a deal this fund participated in
$122M
Portfolio companies 43
Lead investments 2
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.08
Exits 13
Key employees Soon

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Pharmaceutical
  • Health Diagnostics

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of Avidity Partners:
Typical Co-investors
Avidity Partners is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after Avidity Partners:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Axxon Capital Boston, Massachusetts, United States
Bright Technologies Fund Lugano, Switzerland, Ticino
Capstar Partners Austin, Texas, United States
Climate-KIC Accelerator London Belgium, Brussels, Brussels Hoofdstedelijk Gewest
Faad Network Delhi, India, New Delhi
Fluid Capital Group -
FMC Ventures Pennsylvania, Philadelphia, United States
Heller Financial Chicago, Illinois, United States
Instillo Germany, Saarland, Überherrn
Johnson Family Trust -
Level 5 Capital Partners Atlanta, Georgia, United States
Medina Heights Capital Partners New York, New York, United States
Prisma Energy International Houston, Texas, United States
Rooks Nest Ventures England, London, United Kingdom
Rosalind Advisors -
Seneca Ventures Seattle, United States, Washington
Srikrung Wattana Group -
Steigen -
Yueyou Touzi China, Hangzhou, Zhejiang

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

MBrace Therapeutics

Biotechnology
$85M14 Nov 2023 San Diego, California, United States

Octave

Health Care
Personal Health
Wellness
$52M15 Jun 2023 San Francisco, California, United States

Upstream Health

Fitness
Health Care
Information Technology
Wellness
$140M02 Dec 2022 United Kingdom, England, United Kingdom

UpStream Care

Health Care
Wellness
$140M01 Dec 2022 Greensboro, North Carolina, United States

Nested Therapeutics

Health Care
Health Diagnostics
Medical
Medical Device
$90M06 Oct 2022 Cambridge, Massachusetts, United States

Prellis Biologics

3D Printing
Biotechnology
Health Care
Medical
$35M10 Aug 2022 San Francisco, California, United States

Dianthus Therapeutics

Biopharma
Biotechnology
Health Care
$100M19 Apr 2022 Waltham, Massachusetts, United States

Endeavor BioMedicines

Biotechnology
$101M07 Feb 2022 California, United States

AN2 Therapeutics

Biotechnology
Health Care
Pharmaceutical
$80M07 Jan 2022 California, United States
News
GentiBio Raises $157M in Series A Financing

– GentiBio, Inc. from Boston develops engineered regulatory T cells (Tregs) therapies for immunology.
– Series A $157m round was led by Matrix Capital Management with participation from Avidity Partners, JDRF T1D Fund, OrbiMed, RA Capital Management, and Novartis Venture Fund.
– The company intends to use the funds to advance its potential functional cure for Type 1 Diabetes (T1D) to the clinic alongside multiple other pipeline programs in chronic autoimmunity and autoinflammation.

Zentera Therapeutics Raises $75M in Series b Funding

– Zentera Therapeutics, a Shanghai, China-based clinical-stage biopharmaceutical company, raised $75M in Series B funding.
– The round was led by OrbiMed Advisors Asia and Tybourne Capital Management with participation from Avidity Partners, Casdin Capital, Surveyor Capital, Farallon Capital Management, Lilly Asia Ventures, Logos Capital, Perceptive Advisors, Redmile Group and Viking Global Investors.
– The company intends to use the funds to advance the development of three Zentalis-discovered oncology clinical candidates as well as business development for future pipeline additions in China.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent Avidity Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 48
Average round size 122M
Peak activity year 2021
Lead investments 2
Follow on index 0.08
Exits 13
Group Appearance index 1.00

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

MBrace Therapeutics

Biotechnology
$85M14 Nov 2023 San Diego, California, United States

Octave

Health Care
Personal Health
Wellness
$52M15 Jun 2023 San Francisco, California, United States

Upstream Health

Fitness
Health Care
Information Technology
Wellness
$140M02 Dec 2022 United Kingdom, England, United Kingdom

UpStream Care

Health Care
Wellness
$140M01 Dec 2022 Greensboro, North Carolina, United States

Nested Therapeutics

Health Care
Health Diagnostics
Medical
Medical Device
$90M06 Oct 2022 Cambridge, Massachusetts, United States

Prellis Biologics

3D Printing
Biotechnology
Health Care
Medical
$35M10 Aug 2022 San Francisco, California, United States

Dianthus Therapeutics

Biopharma
Biotechnology
Health Care
$100M19 Apr 2022 Waltham, Massachusetts, United States

Endeavor BioMedicines

Biotechnology
$101M07 Feb 2022 California, United States

AN2 Therapeutics

Biotechnology
Health Care
Pharmaceutical
$80M07 Jan 2022 California, United States
Crunchbase icon

Content report

The following text will be sent to our editors: